Developing small molecule drugs is exceptionally challenging. Pharmaceutical companies face high costs, huge attrition rates and considerable risk. One particular difficulty lies in getting a small molecule to the clinic.

Here, we summarize what is needed to move a small molecule candidate from R&D to GMP-compliant phase I clinical manufacturing, focusing on the critical considerations across chemical synthesis, analytics and materials science.